Stay updated with breaking news from A2ar. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CLINICAL DATA BUILDS UPON BODY OF EVIDENCE SUGGESTING EXS-21546 IS A HIGHLY POTENT AND SELECTIVE A2AR INHIBITOR WITH LOW CNS EXPOSURE EXSCIENTIA ANTICIPATES... | June 14, 2022
(0) NEW YORK, NY / ACCESSWIRE / April 6, 2021 / Tarus Therapeutics Inc., an innovative biotechnology company developing adenosine receptor antagonists for cancer immunotherapy, today announced that it has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to proceed with a clinical study of TT-10, an oral small molecule drug targeting the Adenosine A2A receptor (A2AR). Tarus plans to initiate a Phase 1a/1b study in the third quarter of 2021 to evaluate TT-10 in patients with advanced solid tumors both as a monotherapy and in co...